Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 140-145

  Skoumas, John ^a   Liontou, Catherine ^a   Chrysohoou, Christina ^a   Masoura, Constantina ^a   Aznaouridis, Konstantinos ^a   Pitsavos, Christos ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Diabetes mellitus; Familial combined hyperlipidemia; Heterozygous familial hypercholesterolemia; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; RISK FACTOR; THYROID FUNCTION; TREATMENT DURATION; ANTHROPOMETRY; BLOOD PRESSURE; CHEMISTRY; COMPLICATION; DIABETES COMPLICATIONS; GENETICS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPIDEMIAS; INCIDENCE; LIFESTYLE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPIDEMIAS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84907703863     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.047     Document Type: Article

References (42)

1. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
2. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEngl J Med 2003, 348:383-393.
3. Gaede P., Pederson O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004, 53:S39-S47.
4. Danaei G., Lawes C.M., Vander Hoorn S., et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006, 368:1651-1659.
5. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl.1):S11-S66.
6. Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
7. Sampson U.K., Linton M.F., Fazio S. Are statins diabetogenic?. Curr Opin Cardiol 2011, 26:342-347.
8. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAm Med Assoc 2011, 305:2556-2564.
9. Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol 2013, 12(Suppl.1):S3.
10. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.
11. Veerkamp M., de Graaf J., Bredie S., et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002, 22:274-278.
12. Voors-Pette C., de Bruin T.W. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis 2001, 157:481-489.
13. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490. for the European Atherosclerosis Society Consensus Panel.
14. Panagiotakos D.B., Pitsavos C., Skoumas J., et al. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987-2002). Curr Med Res Opin 2003, 19:89-94.
15. Dedoussis G., Skoumas J., Pitsavos C., et al. FH clinical phenotype in Greek patients with LDL-R defective vs. negative mutations. Eur J Clin Invest 2004, 34:402-409.
16. Jansen A.C., van Aalst-Cohen E.S., TanckMW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. JIntern Med 2004, 256:482-490.
17. Gaddi A., Cicero A.F., Odoo F.O., et al. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date; Atherosclerosis and Metabolic Diseases Study Group. Vasc Health Risk Manag 2007, 3:877-886.
18. Gaddi A., Galetti C., Pauciullo P., et al. Familial combined hyperlipoproteinemia: Experts' panel position on diagnostic criteria for clinical practice: Committee of experts of the Atherosclerosis and Dysmetabolic Disorders, Study Group. Nutr Metab Cardiovasc Dis 1999, 9:304-311.
19. de Graaf J., van der Vleuten G., Stalenhoef A.F. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004, 4:229-240.
20. Aguilar Salinas C., Zamora M., Gomez-Diaz R., et al. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med 2004, 2:203-209.
21. Assmann G., Schulte H. Relation of HDL-cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): prospective Cardiovascular Munster Study. Am J Cardiol 1992, 70:733-737.
22. Mancia G., De Backer G., Dominiczak A., et al. The task force for the management of arterial hypertension of the European Society of Hypertension, the task force for the management of arterial hypertension of the European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
23. American Diabetes Association Standards of medical care in diabetes. Diabetes Care 2010, 33(Suppl.1):S11-S61.
24. Skoumas I., Masoura C., Aznaouridis K., et al. Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia. Circ J 2013, 77:163-168.
25. McKenney J.M., Jones P.H., Adamczyk M.A., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003, 19:689-698.
26. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152-160. STELLAR Study Group.
27. Nicholls S.J., Brandrup-Wognsen G., Palmer M., et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010, 105:69-76.
28. Weng T.C., Yang Y.H., Lin S.J., et al. Asystematic review and meta-analysis on the therapeutic equivalence of statins. JClin Pharm Ther 2010, 35:139-151.
29. Panz V., Immelman A., Paiker J., et al. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord 2012 Oct, 10:351-357.
30. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
31. Rajpathak S.N., Kumbhani D.J., Crandall J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:192-199.
32. Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013, 111:1123-1130.
33. Panagiotakos D.B., Pitsavos C., Chrysohoou C., et al. Prevalence and five-year incidence (2001-2006) of cardiovascular disease risk factors in a Greek sample: the ATTICA study. Hellenic J Cardiol 2009, 50:388-395.
34. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999, 142:105-112.
35. Hopkins P.N., Stephenson S., Wu L.L., et al. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001, 87:547-553.
36. de Sauvage Nolting P.R., Defesche J.C., Buirma R.J., et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. JIntern Med 2003, 253:161-168.
37. Besseling J., Kindt I., Hof M., et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014, 233:219-223.
38. Narayanan R.P., Gittins M., Siddals K.W., et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability. Eur J Endocrinol 2013, 168:543-548.
39. Carr M.C., Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. JClin Endocrinol Metab 2004, 89:2601-2607.
40. ter Avest E., Abbink E.J., de Graaf J., et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005, 35:558-564.
41. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
42. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.